Products
Insulin detemir is commercially available as an injectable (Levemir). It has been approved in many countries since 2003.
Structure and properties
Insulin detemir (C267H402O76N64S6, Mr = 5916.9 g/mol) has an identical primary sequence to human insulin except for the removed threonine at position B30 of the B chain and an added molecule of myristic acid to the lysine at position B29.
Effects
Insulin detemir (ATC A10AE05) has blood glucose-lowering properties. It is a soluble, long-acting, basal insulin analog with a flat action profile and an extended duration of action of up to 24 hours. The long duration of action is a consequence of binding to albumin, which is mediated by myristic acid.
Indications
For the treatment of diabetes mellitus (type 1 or 2).
Dosage
According to the SmPC. The injection solution is injected subcutaneously under the skin with an insulin pen once or twice daily.
Contraindications
- Hypersensitivity
Full details of precautions and drug interactions can be found in the Drug Information Leaflet.
Interactions
Numerous drugs have an effect on blood glucose levels.
Adverse effects
The most common possible adverse effects include hypoglycemia, injection site reactions such as pain, redness, and itching, and allergic reactions.
